PHARMACY

GE Healthcare partners with Kryptiq for use of eScriptMessenger

BY Drew Buono

BARRINGTON, Ill. General Electric’s healthcare unit, GE Healthcare IT, has signed with the information technology solutions company Kryptiq that will enable GE to exclusively distribute Kryptiq’s eScriptMessenger in conjunction with its Centricity Electronic Medical Records and Centricity Practice Solution to help speed up and offer easy access in managing prescription activities.

Under the joint agreement, GE will also work with Kryptiq to expand current connection capabilities and continue to address upcoming EMR certification and ePrescribing regulatory requirements. Kryptiq’s eScriptMessenger for GE’s Centricity EMR and Centricity Practice Solution will be sold exclusively through GE.

“As the Kryptiq ePrescribing solution is already readily accepted by several thousand of our Centricity EMR customers, we are excited to build on this existing alliance to meet the evolving needs of our customers with one point of purchase,” said James Corrigan, vice president and general manager, GE Healthcare IT. “Our guiding principle is to provide the best user experience and building on this relationship will allow even more customers to connect ePrescribing seamlessly into current workflows.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Juvaris tests flu vaccine addition

BY Alaric DeArment

NEW YORK Burlingame, Calif.-based Juvaris BioTherapeutics is testing an adjuvant for flu vaccines.

JVRS-100, as the drug is known, is designed to augment vaccines by stimulating the immune system. Testing will involve 128 patients who will receive the drug ad an flu vaccine.

The trial will test the safety and tolerability of the drug.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Teva announces generic Wellbutrin XL and Zyrtec syrup

BY Drew Buono

NORTH WALES, Pa. Teva Pharmaceuticals has announced the availability of two new generic drugs, Cetirizine hydrochloride syrup, the generic of Pfizer’s allergy medication Zyrtec syrup and Budeprion XL 150 mg, the generic of GlaxoSmithKline’s seasonal affective disorder medication Wellbutrin XL 150 mg.

Cetirizine Hydrochloride Syrup is available in a 5 mg/5 mL strength, in bottle sizes of 120 mL and 473 mL. Also, with the addition of this new strength, Teva now offers Budeprion XL tablets in 150 mg and 300 mg strengths, in bottle sizes of 30 and 500.

Zyrtec syrup has sales of $177 million in 2007 and Wellbutrin XL had sales of $992 million in 2007, according to drugs.com.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?